Biopharmaceutical companies are increasingly challenged to create a drug pricing strategy that both rewards value and innovation, and promotes affordability and access. During this webinar, PwC’s Health Research Institute will review findings from a new global survey of industry executives, and provide analysis and commentary on key drug pricing issues, including:
- US policy and regulatory changes and implications for manufacturers
- Market access and pricing issues in global markets
- Contracting and reimbursement models
- Price transparency
- Patient affordability
Individuals working in biopharma commercial, pricing and reimbursement, market access, risk and regulatory, and emerging products (such as gene therapies, orphan drugs and digital therapeutics) will benefit from case examples and market analyses of drug pricing challenges, as well as opportunities to improve pricing practices for new and marketed products.